NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » Contract Research Orgs » Sundia MediTech Company,Ltd. back to previous page show list
Sundia MediTech Company,Ltd. »06/07/2009 [Industry news]
Dr Chen joins Sundia chemistry services team

Sundia MediTech, an integrated pharmaceutical and biotech R&D outsourcing company in Shanghai, China, has appointed Dr Chen Chen as the Senior Vice President of Chemistry Services.

 
Sundia MediTech, an integrated pharmaceutical and biotech R&D outsourcing company in Shanghai, China, has appointed Dr Chen Chen as the Senior Vice President of Chemistry Services. Prior to joining Sundia, Dr Chen worked at Neurocrine Biosciences, a drug discovery and development company in San Diego, US for 15 years, from a staff scientist to Senior Director of Medicinal Chemistry of Neurocrine. In his research and management positions at Neurocrine, Dr Chen has achieved many outstanding scientific and industrial accomplishments, including development of two small molecule antagonists, NBI-42902 and elagolix (NBI-56418), of the gonadotropin-releasing hormone receptor into clinical studies. Elagolix, is finishing phase II trials by Neurocrine for the treatment of endometriosis. Dr Chen designed, synthesized and developed NBI-30775 (R121919), a small molecule antagonist of the corticotrophin-releasing factor receptor as the first-in-class compound advanced into clinical trials for depression/anxiety. Dr Chen also discovered NBI-31772, the first small molecule inhibitor for the insulin-like growth factor-I/IGF-binding protein. In addition, Dr Chen identified the first selective antagonist of the melanocortin-5 receptor, and discovered numerous agonists and antagonists for the melanocortin-4 receptor for eating disorders. Dr Chen has extensive experience in CNS drug research and GPCRs as drug targets. His knowledge also includes neuropathic pain and metabolic disorders. His research interests extend to clinic and preclinic pharmacokinetics of small molecules and the relationship with their chemical properties. It is an honour for Sundia to have world class leading scientists as Dr Chen in our senior management team. As our clients worldwide are bringing more and more high technical level drug discovery programs to Sundia, Dr Chen and other scientists at Sundia with excellent track record in drug discovery will make Sundia highly competent to deliver outstanding services to our clients, said, Dr Xiaochuan Wang, Chairman, Sundia.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.